Table 2

Relationship between Ezrin protein overexpression and clinicopathological features of gastric adenocarcinoma
Clinical features No. of cases Strongly positive cases (%) P-value
Age
 <50 96 60 (62.5%) NS
 51-69 181 92 (50.8%)
 ≥70 29 16 (55.2%)
Gender NS
 Male 164 102 (62.2%)
 Female 113 66 (58.4%)
Lauren Types <0.05, a
 Intestinal type 117 77 (65.8%)
 Diffuse type 139 85 (61.2%)
 Mixed type 21 6 (28.6%)
WHO’s Histological Types NS
 Well-diff. ade. 85 42 (49.4%)
 Moderately-diff. ade. 103 54 (52.4%)
 Poorly-diff. ade. 59 50 (84.7%)
 Undifferentiated ade. 5 3 (60.0%)
 Signet ring cell carcinoma 9 5 (55.6%)
 Mucinous ade. 16 14 (87.5%)
LN Metastasis <0.01
 Negative 151 53 (35.1%)
 Positive 126 115 (91.3%)
Clinical Stage <0.05, b
 0 39 14 (35.9%)
 IA 47 12 (25.5%)
 IB 51 23 (45.1%)
 II 75 59 (78.7%)
 IIIA 59 54 (91.5%)
 IV 6 6 (100%)
Disease Free Survival <0.01
 ≥3 years 152 53 (34.9%)
 <3 years 125 115 (92.0%)

ade.: Adenocarcinoma; diff.: differentiated; NS: not significant. * Strongly positive: ++ and +++.

a: Intestinal & Diffuse types vs Mixed type.

b: Stage 0 + Stage IA + Stage IB vs Stage II + Stage IIIA + Stage IV.

Jin et al.

Jin et al. Diagnostic Pathology 2012 7:135   doi:10.1186/1746-1596-7-135

Open Data